Eli Lilly and Company (NYSE:LLY) Price Target Lowered to $1,190.00 at Citigroup

Eli Lilly and Company (NYSE:LLY - Get Free Report) had its price target reduced by equities researchers at Citigroup from $1,250.00 to $1,190.00 in a research note issued to investors on Tuesday,Benzinga reports. The firm presently has a "buy" rating on the stock. Citigroup's price objective points to a potential upside of 47.85% from the company's previous close.

Several other research analysts have also recently weighed in on the stock. Wells Fargo & Company decreased their price objective on shares of Eli Lilly and Company from $1,000.00 to $970.00 and set an "overweight" rating for the company in a report on Tuesday. Truist Financial increased their price target on Eli Lilly and Company from $1,000.00 to $1,033.00 and gave the company a "buy" rating in a report on Thursday, October 10th. Redburn Atlantic upgraded Eli Lilly and Company to a "hold" rating in a research note on Monday, November 4th. StockNews.com upgraded Eli Lilly and Company from a "hold" rating to a "buy" rating in a research report on Wednesday, January 22nd. Finally, Barclays lowered their target price on Eli Lilly and Company from $1,025.00 to $975.00 and set an "overweight" rating on the stock in a report on Thursday, October 31st. Four analysts have rated the stock with a hold rating and eighteen have issued a buy rating to the company. According to data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $997.22.

Eli Lilly and Company Stock Down 0.4 %

NYSE LLY traded down $3.30 during mid-day trading on Tuesday, reaching $804.87. The stock had a trading volume of 2,792,064 shares, compared to its average volume of 4,070,577. The stock has a market cap of $764.08 billion, a PE ratio of 87.01, a price-to-earnings-growth ratio of 1.59 and a beta of 0.41. Eli Lilly and Company has a 1 year low of $637.00 and a 1 year high of $972.53. The company has a debt-to-equity ratio of 2.03, a current ratio of 1.27 and a quick ratio of 0.97. The company has a fifty day moving average price of $778.30 and a 200 day moving average price of $847.30.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last posted its quarterly earnings results on Wednesday, October 30th. The company reported $1.18 earnings per share for the quarter, missing the consensus estimate of $1.52 by ($0.34). Eli Lilly and Company had a return on equity of 71.08% and a net margin of 20.48%. The business had revenue of $11.44 billion during the quarter, compared to analysts' expectations of $12.09 billion. During the same quarter in the prior year, the firm earned $0.10 EPS. The firm's revenue for the quarter was up 20.4% compared to the same quarter last year. On average, research analysts expect that Eli Lilly and Company will post 12.98 earnings per share for the current year.

Eli Lilly and Company declared that its board has authorized a stock buyback plan on Monday, December 9th that authorizes the company to buyback $15.00 billion in shares. This buyback authorization authorizes the company to purchase up to 2% of its shares through open market purchases. Shares buyback plans are typically a sign that the company's board believes its stock is undervalued.

Insider Buying and Selling at Eli Lilly and Company

In other Eli Lilly and Company news, CAO Donald A. Zakrowski sold 900 shares of the stock in a transaction dated Friday, November 8th. The shares were sold at an average price of $803.38, for a total transaction of $723,042.00. Following the completion of the transaction, the chief accounting officer now owns 5,480 shares of the company's stock, valued at $4,402,522.40. This represents a 14.11 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. 0.13% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently modified their holdings of the company. Algert Global LLC lifted its holdings in shares of Eli Lilly and Company by 27.9% in the 2nd quarter. Algert Global LLC now owns 504 shares of the company's stock valued at $456,000 after acquiring an additional 110 shares during the last quarter. Pathway Financial Advisers LLC lifted its stake in shares of Eli Lilly and Company by 4.2% in the 2nd quarter. Pathway Financial Advisers LLC now owns 1,101 shares of the company's stock valued at $982,000 after purchasing an additional 44 shares during the last quarter. Advisory Alpha LLC boosted its holdings in shares of Eli Lilly and Company by 6.5% in the 2nd quarter. Advisory Alpha LLC now owns 3,208 shares of the company's stock worth $2,905,000 after purchasing an additional 195 shares during the period. Ted Buchan & Co bought a new position in shares of Eli Lilly and Company during the 2nd quarter valued at approximately $1,780,000. Finally, Granite Bay Wealth Management LLC purchased a new stake in Eli Lilly and Company during the 2nd quarter valued at $323,000. 82.53% of the stock is currently owned by institutional investors.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.